PYC Therapeutics Limited (ASX:PYC)

Australia flag Australia · Delayed Price · Currency is AUD
1.305
-0.005 (-0.38%)
Apr 28, 2026, 4:10 PM AEST
17.04%
Market Cap 1.28B
Revenue (ttm) 20.56M
Net Income (ttm) -47.56M
Shares Out 983.26M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 528,928
Average Volume 1,068,950
Open 1.320
Previous Close 1.310
Day's Range 1.290 - 1.320
52-Week Range 0.847 - 1.755
Beta 1.01
RSI 55.40
Earnings Date May 22, 2026

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 5
Stock Exchange Australian Securities Exchange
Ticker Symbol PYC
Full Company Profile

Financial Performance

In fiscal year 2025, PYC Therapeutics's revenue was 23.49 million, an increase of 6.51% compared to the previous year's 22.06 million. Losses were -50.30 million, 33.3% more than in 2024.

Financial Statements

News

There is no news available yet.